Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
European Urology
|
April 21, 2023
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
Primo N Lara, Edward Mayerson, Erik Gertz, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 16, 2004
Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists
Robert J DeVita, Mamta Parikh, Jinlong Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2022
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma
Sarmad Sadeghi, David Quinn, Tanya Dorff, et al.
JCO Precision Oncology
|
April 10, 2018
TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies
Primo N Lara, Andreas M Heilmann, Julia A Elvin, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
JAMA Oncology
|
August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial
Sumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Cancer Research Communications
|
October 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
Mamta Parikh, Nataliya V Uboha, Naoko Takebe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
European Urology
|
April 21, 2023
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
Primo N Lara, Edward Mayerson, Erik Gertz, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 16, 2004
Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists
Robert J DeVita, Mamta Parikh, Jinlong Jiang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2022
EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma
Sarmad Sadeghi, David Quinn, Tanya Dorff, et al.
JCO Precision Oncology
|
April 10, 2018
TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies
Primo N Lara, Andreas M Heilmann, Julia A Elvin, et al.
Cancer Research Communications
|
June 26, 2024
A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
JAMA Oncology
|
August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial
Sumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Cancer Research Communications
|
October 17, 2025
The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)
Mamta Parikh, Nataliya V Uboha, Naoko Takebe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 7, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
European Urology Oncology
|
March 24, 2024
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Mamta Parikh, Catherine Tangen, Maha H A Hussain, et al.
Page
of 5